Pfizer’s sickle cell disease candidate fails Phase III trial

Inclacumab was generally well tolerated in THRIVE-131

Novo Nordisk's Wegovy approved in the US for the treatment of MASH

The accelerated approval is supported by results from part 1 of the ESSENCE trial

Tonix receives FDA approval of Tonmya for treatment of fibromyalgia

Centrient Pharmaceuticals joins UNGC

Reinforcing commitment to ethical and sustainable growth

Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India

NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India

Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg

This is the group’s first NoC approval in Canada

AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata

The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage

Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs

These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs

Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure

Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr